中文摘要：

中草药基于它的唯一的理论系统和实质的植物疗法为不含酒精的脂肪肝疾病(NAFLD ) 开发了新治疗。在这评论， 21 繁体中文植物在 NAFLD 的治疗为他们的潜在的利益被介绍。他们的多数被 multicenter 被试验性的研究和很少评估临床的试用。是的草药的单体 berberine 和 resveratrol，从蓼 hypoleucum Ohwi 的摘录，和 Artemisia sacrorum Ledeb，和包括 Yinchenhao 煎的公式(， YCHD ) ， Qushi Huayu 煎(， QSHYD ) ，并且 Danning 药片() 在他们的治疗学的潜力上详细被讨论。大多数这些草药的药被证明在 vitro 并且在 vivo 改进 NAFLD 的生物化学、组织学的变化。另外，他们的治疗学的活动与通过腺苷禁止类脂化合物累积被联系激活 monophosphate 的蛋白质 kinase 激活或 upregulating 低密度的脂蛋白受体(LDLR ) 表示，减轻类脂化合物 peroxidation，并且减少煽动性的 cytokines 的生产。尽管这些草药的药的功效和安全需要在 multicenter 被评估大规模临床的试用，中国药为阻止并且对待 NAFLD 有希望、有效疾病。

英文摘要：

Chinese herbal medicine has developed new therapies for nonalcoholic fatty liver disease （NAFLD） based on its unique theory system and substantial herb remedies. In this review, 21 traditional Chinese herbs were introduced for their potential benefit in the treatment of NAFLD. Majority of them are evaluated by experimental studies and few by multicenter clinical trials. Herbal monomers as berberine and resveratrol, extracts from Polygonum hypoleucum Ohwi, and Artemisia sacrorum Ledeb., and formulae including Yinchenhao Decoction （~.~.~, YCHD）, Qushi Huayu Decoction （~＇~. ~.~, QSHYD）, and Danning Tablet （）~？）~） were discussed in detail on their therapeutic potentials. Most of these herbal medicines were proved to improve biochemical and histological changes of NAFLD both in vitro and in vivo. Also, their therapeutic activities were associated with inhibiting lipid accumulation through adenosine monophosphate-activated protein kinase activation or upregulating low-density lipoprotein receptor （LDLR） expression, alleviating lipid peroxidation, and reducing the production of inflammatory cytokines. Although the efficacy and safety of these herbal medicines needed to be evaluated in multicenter large-scale clinical trials, Chinese medicine is promising and effective for preventing and treating NAFLD disease.